Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering-Plough Merger Offers Merck OTC Business, Zegerid Switch Rights

This article was originally published in The Tan Sheet

Executive Summary

Merck stands to pick up the switch rights to the proton pump inhibitor Zegerid at the head of a strong switch program if its planned acquisition of Schering-Plough succeeds

You may also be interested in...



Merck Settles Class Suit Targeting Coppertone Claims, Denies Wrongdoing

Merck agrees to pay a maximum of $10 million to consumers to settle class-action case and to comply with labeling and claims regulations that will become law in December for most firms under an FDA final rule. The settlement in federal court resolves separate litigation against Coppertone filed in California state court.

Merck Looks To “Exploit” Switches With Exit From J&J Joint Venture

Merck gains flexibility to pursue Rx-to-OTC switches, such as allergy drug Clarinex and cholesterol treatment Zetia by exiting its OTC joint venture with Johnson & Johnson.

Merck Looks To “Exploit” Switches With Exit From J&J Joint Venture

Merck gains flexibility to pursue Rx-to-OTC switches, such as allergy drug Clarinex and cholesterol treatment Zetia by exiting its OTC joint venture with Johnson & Johnson.

Related Content

Topics

UsernamePublicRestriction

Register

PS102720

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel